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Disruption of cholinergic and serotonergic neurotransmitter systems is associated with cognitive, emotional and
behavioural symptoms of Alzheimer's disease (AD). To investigate the responsiveness of these systems in AD we
measured the effects of a single-dose of the selective serotonin reuptake inhibitor citalopram and acetylcholin-
esterase inhibitor galantamine in 12 patients with AD and 12 age-matched controls on functional brain con-
nectivity with resting state functional magnetic resonance imaging. In this randomized, double blind, placebo-
controlled crossover study, functional magnetic resonance images were repeatedly obtained before and after
dosing, resulting in a dataset of 432 scans. Connectivity maps of ten functional networks were extracted using a
dual regression method and drug vs. placebo effects were compared between groups with a multivariate analysis
with signals coming from cerebrospinal fluid and white matter as covariates at the subject level, and baseline and
heart rate measurements as confound regressors in the higher-level analysis (at p< 0.05, corrected). A galant-
amine induced difference between groups was observed for the cerebellar network. Connectivity within the
cerebellar network and between this network and the thalamus decreased after galantamine vs. placebo in AD
patients, but not in controls. For citalopram, voxelwise network connectivity did not show significant
group treatment interaction effects. However, we found default mode network connectivity with the precuneus
and posterior cingulate cortex to be increased in AD patients, which could not be detected within the control
group. Further, in contrast to the AD patients, control subjects showed a consistent reduction in mean connectivity
with all networks after administration of citalopram. Since AD has previously been characterized by reduced
connectivity between the default mode network and the precuneus and posterior cingulate cortex, the effects of
citalopram on the default mode network suggest a restoring potential of selective serotonin reuptake inhibitors in
AD. The results of this study also confirm a change in cerebellar connections in AD, which is possibly related to
cholinergic decline.1. Introduction
In Alzheimer's disease (AD), destruction of neural tissue leads to loss
of cholinergic nuclei in the basal forebrain and depleted cholinergic
innervation towards the cerebral cortex, thalamus and hippocampus
(Mesulam and Geula, 1988; Muir, 1997; Schliebs and Arendt, 2011).
Acetylcholinesterase inhibitors (AChEIs) prevent the breakdown of
acetylcholine and are often used as drug treatment to improve the
cognitive symptoms of AD (Pepeu and Giovannini, 2009; Soreq andute of Psychology Unit Methodol
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rotonin) activity plays a role in the cognitive deterioration (Claeysen
et al., 2015; Geldenhuys and Van der Schyf, 2011), as well as in behav-
ioural and mood changes that frequently accompany AD (Meltzer et al.,
1998; Ownby et al., 2006). The cholinergic and serotonergic systems act
in concert with each other with regard to functions like learning and
memory (McEntee and Crook, 1991; Richter-Levin and Segal, 1993;
Riekkinen et al., 1994), further suggesting the involvement of both sys-
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Table 1
Demographics of mild AD patients and controls.
AD patients Controls
N 12 12
Age (Mean SD) 74.0 5.2 73.1 5.2
Age range 65–81 64–79
Male/female 6/6 6/6
MMSE (Mean SD) 22.3 2.5 29.3 0.9
MMSE range 19–28 28–30
BMI (kg/m2) range 22–30 22–31
Abbreviations: AD¼ Alzheimer's disease; SD¼ standard deviation; MMSE¼Mini
Mental State Examination; BMI¼ body mass index.
B.L. Klaassens et al. NeuroImage 199 (2019) 143–152Single-dose administration of compounds that inhibit or excite syn-
aptic activity can alter brain connectivity during rest, reflecting the
responsiveness of neurotransmitter networks and related functions
(Khalili-Mahani et al., 2015; Kleinloog et al., 2015; Niesters et al., 2014).
This pharmacological ‘challenge’ technique is aimed at discovering the
underlying neurobiological mechanisms behind drug action and
neurotransmitter-related disease. The approach seems especially relevant
for measuring deviant functional processes in AD, which is conceived as a
disorder of both large-scale network disconnections (Delbeuck et al.,
2003; Seeley et al., 2009) and decrements in neurotransmission.
Cholinergic network responses that have been studied so far sub-
stantiate the assumption that acetylcholine is involved in memory,
learning and visual perception (Kang et al., 2014; Soreq and Seidman,
2001). A cholinergic challenge caused increased connectivity in healthy
young subjects with regions that are implicated in visual processing,
memory and attention (Klaassens et al., 2017a). Effects of AChEIs on
connectivity in AD patients have only been examined after long-term
cholinergic treatment, and show enhanced connectivity of the default
mode network (DMN) and the interrelated hippocampus (Blautzik et al.,
2016; Goveas et al., 2011; Griffanti et al., 2016; Li et al., 2012; Sol-
e-Padulles et al., 2013; Zaidel et al., 2012). Despite the likelihood of
disrupted serotonin transmission, serotonergic modulation of brain
connectivity has not yet been studied in AD. Acute or short-term treat-
ment with selective serotonin reuptake inhibitors (SSRIs) elicits reduced
connectivity of the DMN and several other cortical and subcortical areas
in healthy subjects (Klaassens et al., 2015; McCabe and Mishor, 2011;
McCabe et al., 2011; Schaefer et al., 2014; Van de Ven et al., 2013; Van
Wingen et al., 2014) and patients with a major depressive disorder (Li
et al., 2013).
In this randomized, placebo-controlled, crossover study, we used
resting state functional magnetic resonance imaging (RS-fMRI) to visu-
alize cholinergic and serotonergic neurotransmitter networks in AD pa-
tients and age-matched controls. We hypothesized that single-dose AChEI
and SSRI administration changes the functional integrity of neural net-
works differently in AD patients compared to controls, and that the
altered connections would mostly apply to regions that are susceptible
for AD related connectivity change such as the hippocampus, thalamus,
precuneus and cingulate cortex (Hafkemeijer et al., 2012; Sheline and
Raichle, 2013). The outcomes of this study will provide fundamental
knowledge on biochemical pathology in dementia, which might even-
tually benefit drug development and efficacy in neurodegenerative
diseases.
2. Material and methods
2.1. Subjects
We included 12 patients with mild AD and 12 gender- and age-
matched controls. The clinical diagnosis of probable AD was estab-
lished according to the revised criteria of the National Institute of
Neurological and Communicative Disorders and Stroke and the Alz-
heimer's Disease and Related Disorders Association (NINCDS-ADRDA)
(McKhann et al., 2011). Following these criteria, AD was diagnosed
based on the presence of cognitive and behavioural symptoms as deter-
mined by objective cognitive assessment and history-taking, that inter-
fere with functioning during work and usual activities, represent a
decline from previous levels, are not due to delirium or other psychiatric
disorders, and concern two of the five specified domains (memory
impairment, executive dysfunction, impaired visuospatial abilities,
impaired language functions and changes in personality and behaviour).
In addition, symptoms had an insidious onset, worsened over time and
initial cognitive deficits included amnestic or non-amnestic decline.
Supporting evidence of temporal lobe or parietal cortex atrophy was
provided by computed tomography (CT) or structural MRI scans. All AD
patients participating in this study were recently diagnosed and had mild
to moderate cognitive deficits. To ensure the exclusion of severe AD144cases, patients with a Mini Mental State Examination (MMSE) score
(Folstein et al., 1975) below 18 were not included in the study.
Furthermore, they were assessed by a physician (i.e. neurologist, geria-
trician) as mentally capable of understanding the implications of study
participation. The age-matched subjects who served as controls had an
MMSE score between 28 and 30 (see Table 1 for demographics). All
subjects underwent a thorough medical screening at the Centre for
Human Drug Research (CHDR) to investigate whether they met the in-
clusion and exclusion criteria. They had a normal history of physical
health and were able to refrain from using nicotine and caffeine during
study days. Exclusion criteria included positive drug or alcohol screen on
study days, regular excessive consumption of alcohol (>4 units/day),
caffeine (>6 units/day) or cigarettes (>5 cigarettes/day), use of
concomitant medication 2 weeks prior to study participation and
involvement in an investigational drug trial 3 months prior to adminis-
tration. The study was approved by the medical ethics committee of the
Leiden University Medical Centre (LUMC). Written informed consent was
obtained from each subject prior to study participation.
2.2. Experimental design
This was a single centre, randomized, double blind, placebo-
controlled crossover study with citalopram 30mg and galantamine
8mg (Klaassens et al., 2018). Each subject received citalopram, galant-
amine and placebo on 3 different days, with a washout period between
study days of at least 7 days. Citalopram has an average time point of
maximum concentration (Tmax) of 2–4 h, with a half-life (T½) of 36 h. For
galantamine, Tmax¼ 1–2 h and T½¼ 7–8 h. To correct for the different
pharmacokinetic (PK) profiles, citalopram 20mg was administered at
T¼ 0 h, followed by a second dose of 10mg at T¼ 1 h (if the first dose
was tolerated). Galantamine was given as a single 8mg dose at T¼ 2 h.
Blinding was maintained by concomitant administration of
double-dummy placebo's at all three time points. All subjects received an
unblinded dose of granisetron 2mg at T¼0.5 h, to prevent the most
common drug-induced adverse effects of nausea and vomiting.
Six RS-fMRI scans were acquired during each study day, two at
baseline and four after administering citalopram, galantamine or placebo
(at T¼ 2.5, 3.5, 4.5 and 6 h) (Fig. 1). Each scan was followed by per-
formance of computerized cognitive tasks (taken twice at baseline) on the
NeuroCart® test battery, for quantifying pharmacological effects on the
CNS (Dumont et al., 2005; Gijsman et al., 2002; Liem-Moolenaar et al.,
2011). Our sample size was based on previous studies (Khalili-Mahani
et al., 2012, 2015; Kleinloog et al., 2015; Klumpers et al., 2012; Niesters
et al., 2012) that showed significant pharmacological effects in repeated
measures designs with 12 subjects. By including multiple measurements
during the Tmax interval, this repeated measures profile increases the
statistical power of the analysis and allows for identification of time
related effects, associated with changing serum concentrations. On each
study day, nine blood samples were taken during the course of the day to
define the PK profile of citalopram, citalopram's active metabolite des-
methylcitalopram and galantamine (Jacobs et al., 2010; Umegaki et al.,
2009). Concentrations of cortisol and prolactin, which reflect central
neuroendocrine effects of SSRIs and AChEIs (Cozanitis et al., 1980; Sagud
B.L. Klaassens et al. NeuroImage 199 (2019) 143–152et al., 2002; von Bardeleben et al., 1989), were investigated as well to
indicate neuropharmacological effects in both groups.2.3. Outcome measures
2.3.1. Pharmacokinetics
PK parameters for citalopram, galantamine and citalopram's active
metabolite desmethylcitalopram were calculated using a non-
compartmental analysis to validate the choice of time points of phar-
macodynamic endpoints (RS-fMRI, NeuroCart®, neuroendocrine mea-
sures). Blood samples were collected in 4mL EDTA plasma tubes at
baseline and 1, 2, 2.5, 3, 3.5, 4.5 and 6 h post dosing, centrifuged (2000 g
for 10min) and stored at 40 C until analysis with liquid
chromatography-tandem mass spectrometry (LC-MS/MS).
2.3.2. Neuroendocrine variables
Blood samples were obtained to determine cortisol and prolactin
concentrations. Serum samples were taken in a 3.5mL gel tube at base-
line (twice) and 1, 2, 2.5, 3.5, 4.5 and 6 h post dosing, centrifuged (2000 g
for 10min) and stored at 40 C until analysis. Serum concentrations
were quantitatively determined with electrochemiluminescence
immunoassay.
2.3.3. NeuroCart® test battery
Each RS-fMRI scan was followed by functional CNS measures in a
separate room using the computerized NeuroCart® test battery
measuring alertness, mood and calmness (Visual Analogue Scales (VAS)
Bond & Lader), nausea (VAS Nausea), vigilance and visual motor per-
formance (Adaptive Tracking task), reaction time (Simple Reaction Time
task), attention, short-term memory, psychomotor speed, task switching
and inhibition (Symbol Digit Substitution Test and Stroop task), working
memory (N-back task) and memory imprinting and retrieval (Visual
Verbal Learning Test) (Bond and Lader, 1974; Borland and Nicholson,
1984; Laeng et al., 2005; Lezak, 2004; Lim et al., 2008; Norris, 1971;
Rogers et al., 2004; Stroop, 1935; Wechsler, 1981). The Visual Verbal
Learning Test was only performed once during each day (at 3 and 4 h post
dosing) as the test itself consists of different trials (imprinting and
retrieval). Duration of each series of NeuroCart® brain function tests was
approximately 20min. To minimize learning effects, training for the
NeuroCart® tasks occurred during the screening visit within 3 weeks
prior to the first study day.
2.3.4. Imaging
Scanning was performed at the LUMC on a Philips 3.0 T Achieva MRI
scanner (Philips Medical System, Best, The Netherlands) using a 32-chan-
nel head coil. All subjects were asked to close their eyes while staying
awake prior to each RS-fMRI session at baseline and after drug or placebo
administration on all three study days. T1-weighted anatomical images
were only acquired at baseline for registration purposes as described in
section 2.4.3.1. To facilitate registration to the anatomical image, each
RS-fMRI scan was followed by a high-resolution T2*-weighted echo-
planar scan.
RS-fMRI data were obtained with T2*-weighted echo-planar imagingFig. 1. Schematic overview of a study day. Each subject received citalopram, galan
acquired, followed by the NeuroCart® CNS test battery. After drug administration, fou
dosing, each time followed by the NeuroCart® test battery. During the day, nine b
thylcitalopram, galantamine, cortisol and prolactin. On each study day there were thr
subjects tolerated the first dose well (did not vomit or feel too nauseous).
145(EPI) with the following scan parameters: 220 whole brain volumes,
repetition time (TR)¼ 2180ms; echo time (TE)¼ 30ms; flip angle¼ 85;
field-of-view (FOV)¼ 220 220 130mm; in-plane voxel resolu-
tion¼ 3.44 3.44mm, slice thickness¼ 3.44mm, including 10% inter-
slice gap; acquisition time 8min. For 3D T1-weighted MRI the following
parameters were used: TR¼ 9.1ms; TE¼ 4.6ms; flip angle¼ 8;
FOV¼ 224 177 168mm; in-plane voxel resolution¼ 1.17  1.17
mm; slice thickness¼ 1.2mm; acquisition time 5min. Parameters of high-
resolutionT2*-weighted EPI scanswere set to: TR¼ 2200ms; TE¼ 30ms;
flip angle¼ 80; FOV¼ 220 220 168mm; in-plane voxel resolu-
tion¼ 1.96 1.96mm; slice thickness¼ 2.0mm; acquisition time 30 s.2.4. Statistical analysis
2.4.1. Pharmacokinetics
Maximum plasma concentrations (Cmax) and time of Cmax (Tmax) were
obtained directly from the plasma concentration data. The area under the
plasma concentration vs. time curve was calculated from time zero to the
time of the last quantifiable measured plasma concentration (AUC0-last).
To investigate differences between groups, PK parameters were analysed
using a mixed effects model with group as fixed effect (SAS for Windows
V9.4; SAS Institute, Inc., Cary, NC, USA).
2.4.2. Neuroendocrine variables and NeuroCart® test battery
Treatment (drug vs. placebo) x group (AD patients vs. controls)
interaction effects on cortisol and prolactin concentrations and Neuro-
cart® measures were investigated using a mixed effects model with
treatment, time, group, visit, treatment by time, treatment by group and
treatment by group by time as fixed effects, subject, subject by treatment
and subject by time as random effects and the average of the period
baseline (pre-dose) values as covariate (SAS for Windows V9.4; SAS
Institute, Inc., Cary, NC, USA). The neuroendocrine data and data of the
Simple Reaction Time task were not normally distributed and therefore
log-transformed before analysis and back transformed after analysis. The
data of the Visual Verbal Learning test were analysed using a mixed ef-
fects model with treatment, group, visit and treatment by group as fixed
effects and subject as random effect.
2.4.3. Imaging
All fMRI analyses were performed using the Functional Magnetic
Resonance Imaging of the Brain (FMRIB) Software Library (FSL, Oxford,
United Kingdom) version 5.0.7 (Jenkinson et al., 2012; Smith et al.,
2004; Woolrich et al., 2009).
2.4.3.1. Data preprocessing. Each individual functional EPI image was
inspected, brain-extracted and corrected for geometrical displacements
due to head movement with linear (affine) image registration (Jenkinson
et al., 2002; Smith, 2002). Head movement was also inspected by
calculating the mean framewise displacement of each RS-fMRI image
(see Supplementary Table 1) (Power et al., 2012), which were all below
half a voxel's width. Images were spatially smoothed with a 6mm
full-width half-maximum Gaussian kernel. Registration parameters for
non-smoothed data were estimated to transform fMRI scans into standardtamine and placebo on three different days. At baseline, two RS-fMRI scan were
r more RS-fMRI scans were acquired at time points T¼ 2.5, 3.5, 4.5 and 6 h post
lood samples were taken to measure the concentrations of citalopram, desme-
ee moments of administration. The second administration only took place when
B.L. Klaassens et al. NeuroImage 199 (2019) 143–152space and co-registered with the brain extracted high resolution
T2*-weighted EPI scans (with 6 degrees of freedom) and T1-weighted
images (using the Boundary-Based-Registration method) (Greve and
Fischl, 2009). The T1-weighted scans were non-linearly registered to the
MNI 152 standard space (the Montreal Neurological Institute, Montreal,
QC, Canada) using FMRIB's Nonlinear Image Registration Tool. Regis-
tration parameters were estimated on non-smoothed data to transform
fMRI scans into standard space after Automatic Removal Of Motion Ar-
tifacts based on Independent Component Analysis (ICA-AROMA
vs0.3-beta). ICA-AROMA attempts to identify and remove motion related
noise components by investigating its temporal and spatial properties. As
recommended, high pass temporal filtering (with a high pass filter of
150 s) was applied after denoising the fMRI data with ICA-AROMA
(Pruim et al., 2015a, 2015b).
2.4.3.2. Estimation of network connectivity. RS-fMRI networks were
extracted from each individual denoised RS-fMRI dataset (24 subjects x 3
days  6 scans¼ 432 datasets) with a dual regression analysis (Beck-
mann et al., 2009; Filippini et al., 2009) based on 10 predefined standard
network templates (Klaassens et al., 2015, 2017a). These standard tem-
plates have been identified using a data-driven approach (Smith et al.,
2009) and comprise the following networks: three visual networks
(consisting of medial, occipital pole, and lateral visual areas), default
mode network, cerebellar network, sensorimotor network, auditory
network, executive control network and left and right frontoparietal
networks. Time series of white matter, measured from the centre of the
corpus callosum, and cerebrospinal fluid (CSF), measured from the centre
of the lateral ventricles, were added as confound regressors in this
analysis to account for non-neuronal signal fluctuations (Birn, 2012).
With the dual regression method, spatial maps representing voxel-to-
network connectivity were estimated for each dataset separately in two
stages and used for higher level analysis. First, the weighted network
maps were used in a spatial regression into each dataset. This stage
generated 12 time series per dataset that describe the average temporal
course of signal fluctuations of the 10 networks plus 2 confound re-
gressors (CSF and white matter). Next, these time series were entered in a
temporal regression into the same dataset, resulting in a spatial map per
network per dataset with regression coefficients referring to the weight of
each voxel being associated with the characteristic signal change of a
specific network. The higher the value of the coefficient, the stronger the
connectivity of this voxel with a given network.
For an overall impression of connectivity alterations during study
days, mean z-values of these regression coefficients within networks were
calculated for each group and study day separately. By comparing the
average of the four post measurements with the average of the two
baseline measurements it was semi-quantitatively inspected how the
average connectivity within each network changed (increased vs.
decreased) during study days. Fisher's exact test was applied to investi-
gate differences between groups in the number of networks with a spe-
cific direction of this global connectivity change.
2.4.3.3. Higher level analysis. Local group treatment interaction effects
of citalopram and galantamine were investigated with non-parametric
combination (NPC) as provided by FSL's Permutation Analysis for
Linear Models tool (PALM vs94-alpha) (Pesarin, 1990; Winkler et al.,
2014, 2016b) and as previously used to investigate differences in phar-
macological effects between young and older adults (Klaassens et al.,
2018). NPC is a multivariate method that offers the possibility to
combine data of separate, possibly non-independent tests, such as our
multiple time points, and investigate the presence of joint effects across
time points, in a test that has fewer assumptions and is more powerful
than repeated-measurements ANOVA or multivariate ANOVA
(MANOVA).
First, tests were performed for each time point using 1000 synchro-
nized permutations, followed by the fit of a generalized Pareto146distribution to the tail of the approximation distribution, thus refining
the p-values at the tail further than otherwise possible with a small
number of permutations (Winkler et al., 2016a). More specifically, to
investigate group treatment interaction effects on voxelwise functional
connectivity with each of the 10 functional networks, four two-sample
t-tests (AD patients: drug - placebo vs. controls: drug - placebo) were
performed for all post-dose time points (T¼ 2.5, 3.5, 4.5 and 6 h), with
average heart rate (beats/m) per RS-fMRI scan as confound regressor
(Khalili-Mahani et al., 2013). The average of the two baseline RS-fMRI
scans was used as covariate as well, by adding the coefficient spatial
map as a voxel-dependent regressor in the model. This will control for the
confounding influence of possibly systematic individual differences and
group differences at baseline level as recently analysed and described in
Klaassens et al. (2017b). The same method was applied for additional
investigation of treatment effects (drug vs. placebo) on the DMN within
the group of AD patients and within the control group as was previously
done for a group of young adults (Klaassens et al., 2017a). To that end,
four one-sample t-tests (drug vs. placebo) were performed for all
post-dose time points (T¼ 2.5, 3.5, 4.5 and 6 h), with average heart rate
(beats/m) per RS-fMRI scan as confound regressor.
Second, to analyse effects across time, the tests for the four time
points were combined non-parametrically via NPC using Fisher's
combining function (Fisher, 1932) and the same set of synchronized
permutations as mentioned above. A liberal mask was used to investigate
voxels within the MNI template, excluding voxels belonging to CSF.
Threshold-free cluster enhancement was applied to the tests at each time
point and after the combination, and the resulting voxelwise statistical
maps were corrected for the familywise error rate using the distribution
of the maximum statistic (Smith and Nichols, 2009; Winkler et al., 2014).
Voxels were considered significant at p< 0.05, corrected.
3. Results
3.1. Pharmacokinetics
PK parameters (Tmax, Cmax and AUC0-last) in AD patients and controls
are summarized in Table 2. There were no PK differences between AD
patients and controls. Fig. 2 shows the individual and median citalopram
and galantamine PK time profiles.
3.2. Neuroendocrine variables and NeuroCart® test battery
There were no significant group treatment interaction effects of
citalopram and galantamine on cortisol and prolactin. See Supplemen-
tary Fig. 1 for cortisol and prolactin levels in AD patients and controls.
For an overview of all NeuroCart® results, we refer the reader to Sup-
plementary Table 2. No significant group treatment interaction effects
were observed for citalopram or galantamine.
3.3. Imaging
3.3.1. Global connectivity changes
Calculations of the pre and post treatment average connectivity
(mean z-values) per network, group and treatment are summarized in
Table 3. Delta scores show that on placebo days connectivity reduced
from pre to post measurement for 6 of the 10 networks in patients with
AD and for 4 of the 10 networks in controls. Fisher's exact test did not
lead to a significant difference in prevalence in number of networks that
showed a decrease in average connectivity (6/10 vs. 4/10).
Table 3 also presents the pre-post changes in global connectivity
during treatment days. The diurnal patterns of network alterations after
galantamine administration were similar between groups as well. The
prevalence in number of networks that showed a decrease in connectivity
in controls (3/10) vs. patients with AD (7/10) did not lead to a significant
difference.
In contrast to placebo and galantamine study days, group differences
Table 2
Pharmacokinetics of citalopram, desmethylcitalopram and galantamine in AD patients and controls.
PK parameters Citalopram Desmethylcitalopram Galantamine
Mean SD Contrasts (p-value) Mean SD Contrasts (p-value) Mean SD Contrasts (p-value)
AD patients Controls AD patients Controls AD patients Controls
Tmax 3.6 1.2 3.4 1.1 0.527 4.3 1.4 4.0 1.3 0.491 5.0 0.9 4.5 1.1 0.306
Cmax 38.8 4.5 41.8 11.7 0.147 3.0 1.3 3.5 1.8 0.395 36.4 8.0 41.8 12.2 0.324
AUC0-last 153.0 19.0 165.0 43.6 0.150 11.1 5.3 13.3 7.1 0.366 84.7 35.7 104.0 40.2 0.151
Abbreviations: AD¼Alzheimer's disease; PK¼ pharmacokinetic; Tmax¼ time point (h) of maximum concentration; Cmax¼maximum concentration (ng/mL); AUC0-
last¼ area under the plasma concentration versus time curve (ng*h/mL).
Fig. 2. Pharmacokinetic profiles. Median (red line) and individual (black
lines) PK profiles for citalopram (left) and galantamine (right) concentrations in
AD patients (a) and controls (b). Vertical bars illustrate the timing of RS-fMRI
acquisition post drug administration. Observations below limit of quantifica-
tion were dismissed.
B.L. Klaassens et al. NeuroImage 199 (2019) 143–152were observed during citalopram occasions. After citalopram adminis-
tration, reduced connectivity was consistently observed for all 10 net-
works in controls, but only in 4 out of 10 networks in patients with AD. A
prevalence of 10/10 vs. 4/10 networks that showed a decrease in con-
nectivity was tested significant (p< 0.05).
3.3.2. Local differences in drug effects between AD patients and controls
A significant group treatment interaction effect of galantamine was
found for connectivity within the cerebellar network (see Table 4 for
specifications and extent of significant effects). In AD patients, galant-
amine induced a decrease in connectivity of the cerebellar network with
the cerebellum, thalamus and brain stem (interaction and main effects
are shown in Fig. 3). In controls, galantamine did not induce connectivity
alterations with the cerebellar network.
There were no significant differences in network effects of citalopram
vs. placebo between AD patients and controls. Within-group analyses
showed that citalopram significantly increased connectivity between the
DMN and precuneus/posterior cingulate cortex (PCC) compared to pla-
cebo in AD patients, but not in controls (Fig. 4). Table 4 shows specifi-
cations and extent of significant effects.1474. Discussion
We investigated functional network alterations after a serotonergic
and cholinergic challenge to gain insight into disruptions of neuro-
transmitter pathways in AD. Comparing AD patients with age-matched
controls, we found a significant group treatment interaction effect
after administration of the AChEI galantamine on cerebellar network
connectivity. Galantamine induced a local decrease in cerebellar con-
nectivity in AD patients, but not in controls. The SSRI citalopram did not
alter regional connectivity differently between groups. However, after
citalopram intake, the observed overall effect of lowered connectivity
among all networks in controls was absent in AD. In addition, although
there was no local interaction effect, a citalopram intensified DMN-
precuneus/PCC connection was only observed in the AD group. To
guarantee appropriate comparison between groups, PK properties and
neuroendocrine effects of both compounds were investigated as well, and
reassuring of equal absorption rates and hormone fluctuations (Seifritz
et al., 1996), that might otherwise have led to spurious group treat-
ment interactions.
4.1. Galantamine effects
This study is the first to investigate single-dose galantamine effects on
resting state functional connectivity in AD, providing novel information
on acute cholinergic alterations of related neural circuits that might
underlie the cognitive improvements during chronic treatment. Acute
AChEI administration usually does not lead to cognitive enhancement in
healthy subjects or AD (Lanctot et al., 2003; Repantis et al., 2010).
Correspondingly, we did not find convincing effects of galantamine on
any NeuroCart® task. This might be the consequence of our small sample
size, which is an obvious restriction of the study. However, despite this
limitation, galantamine did result in a diminished cerebellar network
response in AD patients compared to controls, suggesting that RS-fMRI
could be a sensitive method for measuring acute pharmacological ef-
fects. Most studies in the literature describe enhanced resting state con-
nectivity after AChEI intake in AD patients (Blautzik et al., 2016; Goveas
et al., 2011; Griffanti et al., 2016; Li et al., 2012; Sole-Padulles et al.,
2013; Zaidel et al., 2012). Contrary to our single-dose administration
these studies all pertain to long-term cholinergic treatment. It is possible
that neuroplasticity and modulation of cholinergic pathways over a
longer period of AChEI treatment result in opposite findings. For
example, increases in posterior DMN connectivity of AD patients as
described by Blautzik et al. (2016) were prevalent after 12 but not after 6
months of galantamine treatment, which was interpreted as indicating an
insufficient time delay of 6 months to measure cholinergic effects. Sol-
e-Padulles et al. (2013) demonstrated significant increased DMN con-
nectivity with the right-hemispheric parahippocampal gyrus in treated
compared to untreated AD patients after 12 weeks of AChEI treatment
but were not able to find longitudinal effects on connectivity with the
DMN within treated patients. Of their 8 treated subjects, 5 even showed
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1484.2. Galantamine and the cerebellar network
The reduction of cerebellar-thalamic connectivity in patients with AD
was partly due to an increase in cerebellar connectivity after placebo as
opposed to a decrease after galantamine. This observation underlines the
importance of implementing a placebo-controlled design to investigate
drug effects in comparison to diurnal fluctuations that are observed on
placebo days and, as is the case for the cerebellar network, might show
opposite patterns. Similarly, we found the average cerebellar network
connectivity to decrease after placebo and to increase after galantamine
administration. The average change in global cerebellar network con-
nectivity during placebo days in the control group also indicates a
normalizing effect of galantamine in AD patients, since the mean con-
nectivity after galantamine in patients (mean z¼ 2.85) equals the mean
connectivity after placebo days in controls (mean z¼ 2.87) instead of
after placebo in patients with AD (mean z¼ 3.94).
It is increasingly recognized that the cerebellum is involved in
cognitive and affective processes that are affected in neurodegenerative
diseases (Colloby et al., 2014; Samson and Claassen, 2017; Thomann
et al., 2008). Certain parts of the cerebellum have extensive fibre con-
nections with specific cerebral areas (Buckner et al., 2011; Glickstein and
Doron, 2008) and previous studies have demonstrated robust structural
cerebellar-cortical atrophy connections (Guo et al., 2016) and lower
functional connectivity within a network consisting of the basal ganglia
and cerebellum (Binnewijzend et al., 2012) in dementia. It has also been
suggested that the cerebellum contributes to the DMN, salience and ex-
ecutive control networks, indicating that cortico-cerebellar pathways are
involved in executive and salience functioning, episodic memory and
self-reflection (Habas et al., 2009), and might therefore play a role in
symptoms as seen in AD.
The results of our study might relate to an association between
cholinergic pathways and cerebellar connections in AD. Despite a lack of
dense cholinergic innervation of the mammalian cerebellum, acetyl-
choline seems to excite the cerebellum's muscarinic Purkinje cells and
mossy fibres that are rich in choline acetyltransferase (Jaarsma et al.,
1996, 1997; Kwong et al., 2000; McCance and Phillis, 1968; Mount et al.,
1994). The observed depletion of dendritic Purkinje neurons in AD
(Mavroudis et al., 2010) possibly accounts for altered cholinergic pro-
jections after galantamine as shown in our study, which is also supported
by delayed loss of Purkinje cells after AChEI treatment (Mount et al.,
1994; Seo et al., 2014). Apart from cortical cholinergic input originating
in the nucleus basalis of Meynert, a prominent cholinergic cell group in
the brain stem projects towards the thalamus (Heckers et al., 1992;
McCance et al., 1968). The thalamus receives input from cerebellar
nuclei, which in turn sends signals to all association areas of the cere-
brum, including the prefrontal cortex (Palesi et al., 2015). In line with
these pathways the observed decreased functional connections between
the cerebellum, thalamus and brain stem in our mild AD group might
represent diminished cholinergic trajectories in AD, which may be
related to neuronal loss (Guo et al., 2016). However, caution is needed in
this interpretation, since the exact relation between connectivity change
and neurobiological effects has to be determined with more certainty.
4.3. Citalopram effects on cognitive functions
Citalopram did not affect any behavioural or cognitive state as
measured with the NeuroCart® battery differently between both groups.
Again, this might be due to our relatively small sample size. Moreover,
and most importantly, SSRIs are known to produce very limited behav-
ioural and cognitive change in wake resting conditions after single-dose
administration (Dumont et al., 2005), despite immediate neural effects.
We included the NeuroCart® tests as outcomemeasures to investigate the
sensitivity of RS-fMRI to pharmacological challenges as a method to
examine the role of neurotransmitter systems in AD and to better un-
derstand the neural bases of drug effectiveness. SSRIs are traditionally
not used as medication for cognitive symptoms, but have been proposed
Table 4
Overview of significant citalopram and galantamine effects on functional connectivity as estimated with threshold-free cluster enhancement (p< 0.05, corrected).
Network effect Region (Harvard-Oxford or Cerebellar atlas) z* x y z #
voxels
Cerebellar network R Cerebellum (lobules I-VI) 4.25 20 42 38 414
(galantamine: AD patients> controls) L Cerebellum (lobule VI) 3.91 26 48 34 106
R Cerebellum (crus I and II) 3.91 20 84 26 9
Cerebellar network (AD patients:
galantamine< placebo)
R Cerebellum (lobules I-VI, IX, crus I), middle and inferior temporal gyrus, fusiform
gyrus, temporal occipital fusiform cortex, parahippocampal gyrus
4.22 50 34 10 3108
L Cerebellum (lobules IX, V, VI, crus I) 3.95 12 56 34 540
L Thalamus 4.00 12 12 6 168
R Inferior frontal gyrus, pars opercularis; precentral gyrus 4.50 36 14 22 110
M Brain stem 3.66 4 26 24 66
L Thalamus, brain stem 4.08 8 30 2 22
R Thalamus 4.03 18 8 10 7
L Cerebellum (lobule VIIb, crus II) 2.85 26 72 50 6
R Caudate 4.05 16 10 4 1




Precuneus, PCC 4.34 6 72 26 685
R Intracalcarine cortex, precuneus 3.54 4 64 14 153
Abbreviations: AD¼Alzheimer's disease; L¼ left; R¼ right; M¼midline; PCC¼ posterior cingulate cortex. Voxel dimension¼ 2mm 2mm x 2mm (voxel volume
0.008 mL). *¼ standardized z-value of the uncorrected peak Fisher-statistic (NPC) within regions.
Fig. 3. Galantamine effects on functional network connectivity. A different
effect on connectivity in AD patients compared to controls after galantamine vs.
placebo within the cerebellar network (shown in green) for regions as shown in
blue (top). The included plot visualizes the corresponding average time profiles
of changes in functional connectivity per group for galantamine - placebo con-
ditions (delta z-values with standard errors of the mean as error bars). The 3D
images (bottom) show main galantamine effects per group. In AD patients,
connectivity between the cerebellar network (green) and regions in blue was
decreased, whereas no effect was found within the controls. Coronal and axial
slices are displayed in radiological convention (left¼ right).
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are an integral part of the disease (Leonpacher et al., 2016; Nyth and
Gottfries, 1990; Porsteinsson et al., 2014). The included participants,
motivated to comply with our intensive study program, were perhaps not
representative of patients with AD with additional neuropsychiatric
impairment, lowering the chance on a differentiated responsiveness of
their serotonergic systems. Potentially, 5-HT hypofunction is also
involved in cognitive disturbances of AD, although studies on the effect
of SSRI administration on these aspects in AD patients are scarce (Schmitt
et al., 2006). Combining AChEI treatment with an SSRI seems to improve
global cognitive functioning in AD compared to AChEI treatment alone149(Mowla, 2009), indicating a beneficial interaction between cholinergic
and serotonergic stimulation, which is in line with observations on the
receptor level (Buhot et al., 2000). Although single-dose administration
of SSRIs has a limited measurable impact on healthy subjects in resting
conditions, it has been well established that SSRIs cause changes in
emotional bias in both healthy volunteers (Harmer et al., 2003) and
depressed patients (Harmer et al., 2009b). These studies suggest that
SSRIs cause acute improvements in emotional bias, which might
contribute to the slow resolution of mood impairment (Harmer et al.,
2009a). According to this hypothesis, the therapeutic activity of
CNS-active drugs is not only dependent on its neuropharmacological
mechanism, but also on its interaction with (abnormal) neuronal pro-
cesses. However, there is much less evidence that similar interactions
play a role in other situations, like delayed effects of acute cholinergic
treatment on dementia. Studies of the acute effects of a CNS-active drug
on network connectivity in unchallenged conditions can provide a basis
for a better understanding of its long-term therapeutic effects. At any
rate, our findings confirm the limited cognitive effects of single-dose SSRI
administration (Dumont et al., 2005; Van Laar et al., 1995). A slight
worsening of performance on two subtests of the N-back in the control
group was most likely due to chance. It may also be a reflection of a
non-linear dose-response, as small immediate memory improvements are
most consistently observed in a low (therapeutic) dose range of SSRIs
(Dumont et al., 2005).
4.4. Connectivity change after citalopram
We did not find any citalopram induced network differences between
patients with AD and controls. However, since single-dose serotonergic
stimulation in non-AD subjects mainly shows effects on DMN connec-
tivity, and DMN coherence is most often found to be altered in AD, we
examined drug effects on DMN connectivity within each group sepa-
rately. An increase in DMN-precuneus/PCC connectivity after citalopram
was found in the AD group, which could not be detected within the
control group. We also observed a significant difference between AD
patients and controls in the number of networks that showed a decrease
vs. increase in connectivity after citalopram. The control group showed a
reduction in connectivity after citalopram compared to baseline for all 10
networks, whereas this was only the case for 4 networks in the AD group.
It is remarkable that we found this global connectivity to be enhanced
after serotonergic stimulation in AD because previous studies almost
uniformly show diminished network coherence after SSRI administration
in healthy (Klaassens et al., 2015, 2017a; McCabe and Mishor, 2011;
McCabe et al., 2011; Schaefer et al., 2014; Van Wingen et al., 2014) and
depressed subjects (Li et al., 2013).
Fig. 4. Citalopram effects on functional network con-
nectivity. Increased connectivity in AD patients after cit-
alopram vs. placebo was observed within the DMN (shown
in green) for the precuneus/PCC (shown in red). Plots
visualize the corresponding average time profiles of
changes in functional connectivity for citalopram (dotted
line) and placebo (continuous line) conditions (z-values
with standard errors of the mean as error bars). Coronal
and axial slices are displayed in radiological convention
(left¼ right).
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(Sundermann et al., 2014), which may explain a lowering in connectivity
after SSRI intake as antidepressant effect. AD however, is defined by
decreased DMN-precuneus/PCC connectivity (Binnewijzend et al., 2012;
Damoiseaux et al., 2012; Sheline et al., 2010; Tahmasian et al., 2015).
The precuneus and PCC, both part of the DMN, are specifically implicated
in symptomatology of AD such as impaired episodic memory retrieval,
self-consciousness and visual-spatial imagery (Cavanna and Trimble,
2006; Karas et al., 2007; Rombouts et al., 2005; Sperling et al., 2010;
Zhang and Li, 2012) and opposite findings after pharmacological
enhancement in this study might indicate beneficial neurochemical ef-
fects in AD. Our observations are concordant with the effects of mem-
antine, an N-methyl-d-aspartate (NMDA) receptor antagonist, which is
used to treat moderate and severe cases of AD. Similar to our results,
memantine has been shown to strengthen connectivity of the DMN with
the precuneus in AD, which was interpreted as representing regulariza-
tion of glutamatic levels that, in effect, leads to increased brain metabolic
activity (Lorenzi et al., 2011). Although evidence on the efficacy of SSRIs
as a treatment for cognitive symptoms of dementia is limited, several
studies have demonstrated that serotonin might be an important target of
pharmacological intervention. The serotonin antagonist and reuptake
inhibitor trazodone hydrochloride has recently been discovered as a
potential new disease-modifying treatment for dementia by arresting the
unfolded protein response, and thereby neurodegenerative cell loss, in
mice (Halliday et al., 2017). Another promising feature of SSRIs is the
ability to suppress generation of beta amyloid in CSF of mice and human
volunteers (Sheline et al., 2014), which implies the potential to prevent
accumulation of beta amyloid, which has also been found in the pre-
cuneus of AD patients (Mintun et al., 2005).
5. Conclusions
Whether serotonin dysregulation in AD mostly contributes to
behavioural or cognitive symptoms, or both, has yet to be sorted out. The
absence of group treatment interaction effects after administering cit-
alopram points to relatively similar serotonergic systems in AD patients
and controls. Our single-dose approach makes it difficult to relate con-
nectivity changes after drug administration directly to behavioural ef-
fects. Behavioural challenges of emotional systems are probably required
to elicit drug-induced effects on emotional circuitries. However, studies
under resting state conditions are important, to allow further resolution
of the interactions between serotonergic enhancement and emotional
processing. This will ultimately also demand for long-term treatment
paradigms and larger sample sizes in clinical populations. Nevertheless,
our results suggest that SSRI administration has an enhancing effect on
DMN-precuneus/PCC connectivity, which has been shown to be
decreased in AD (Hafkemeijer et al., 2012). This opposite finding in-
dicates that SSRIs might have an improving effect on memory,
self-referential processes and/or visual-spatial functions. We also confirm
the significance of a cerebellar network in AD (Guo et al., 2016), which
has been largely neglected within dementia research, but might be an
important component associated with cholinergic decline. A challenge
for the future is to unravel how the acute response to these compounds150develops over a longer treatment period and if this response could be
predictive for treatment efficacy in AD.
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